Results 251 to 260 of about 39,021 (326)

Data from Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer

Everett J. Moding, Mohammad Shahrokh Esfahani, Cheng Jin, Angela B. Hui, Barzin Y. Nabet, Yufei Liu, Jacob J. Chabon, Michael S. Binkley, David M. Kurtz, Emily G. Hamilton, Aadel A. Chaudhuri, Chih Long Liu, Zhe Li, Rene F. Bonilla, Alice L. Jiang, Brianna Lau, Pablo Lopez, Jianzhong He, Yawei Qiao, Ting Xu, Luyang Yao, Saumil Gandhi, Zhongxing Liao, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee, Michael F. Gensheimer, Billy W. Loo, Ruijiang Li, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn   +33 more
openalex   +1 more source

Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets

Advances in Pharmacological and Pharmaceutical Sciences, Volume 2026, Issue 1, 2026.
Cervical cancer is a significant global health challenge, ranking as the fourth most prevalent cancer among women worldwide. While human papillomavirus infection is the primary cause, the disease’s progression involves complex molecular mechanisms.
Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Arpita Dua, Pankaj Kumar Tyagi, Anil Kumar Singh, Kuldeep Singh   +6 more
wiley   +1 more source

Personalized ctDNA detection and genomic profiling in the NeoRHEA Study. [PDF]

NPJ Breast Cancer
Stanciu A, Agostinetto E, Papagiannis A, Pipinikas C, Chevalier A, Campbell N, Brandão M, Ameye L, Paesmans M, Besse T, Rothe F, Buisseret L, Taylor D, Neven P, Sotiriou C, Duhoux FP, Vuylsteke P, Ignatiadis M.   +17 more
europepmc   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management.
Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, Stephanie A. Berg, Mehmet A. Bilen, David Braun, Maria I. Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Shilpa Gupta, Naomi Haas, A. Ari Hakimi, Hans Hammers, Daniel Y. C. Heng, Michelle Hirsch, Gopakumar Iyer, Eric Jonasch, Vadim S. Koshkin, Oleksandr Kryvenko, Bryan Lewis, Roger Li, Surena Matin, Benjamin Maughan, David F. McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Dan Petrylak, Sima Porten, Thomas Powles, Brian Rini, Brian Shuch, Arlene Siefker‐Radtke, Guru Sonpavde, S. Srikala Sridhar, Cristina Suarez, Chad Tang, Abhishek Tripathi, Michiel S. Van Der Heijden, Martin Voss, Wenxin Xu, Tian Zhang, Jonathan Rosenberg, Toni K. Choueiri   +53 more
wiley   +1 more source

Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. [PDF]

Blood Adv
Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J.   +14 more
europepmc   +1 more source

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
ABSTRACT The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR‐positive/HER2‐negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral ...
Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H. Barcenas, Suzanne A. Fuqua, Rachel M. Layman, Debu Tripathy   +5 more
wiley   +1 more source

Prognostic factors for poor outcomes and the predictive role of circulating tumor DNA in immunotherapy for advanced non-small cell lung cancer. [PDF]

Medicine (Baltimore)
Zhang WQ, Huang JL, Lin DL, Xu ZD.
europepmc   +1 more source

367P: Clinical characteristics and ctDNA as prognostic tools in KRAS-mutated NSCLC during first line treatment (1L) [PDF]

Paula Espinosa-Olarte, Ester Munera-Maravilla, Pepa Haba García, Ana Blasco, Susana Torres‐Martínez, S. Calabuig Fariñas, Lara Navarro, Atilio Navarro, A. Fernandez Díaz, C. Ferriol Martinez, Eloísa Jantus‐Lewintre, C. Caballero Díaz   +11 more
openalex   +1 more source

Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis. [PDF]

Front Oncol
Pérez-Alfayate R, Paz-Cabezas M, Pérez-Segura P, Sanchez Del Hoyo R, Cabezas-Camarero S.   +4 more
europepmc   +1 more source

Development and validation of a circulating tumor DNA-based machine learning model for predicting immunotherapy response in non-small cell lung cancer. [PDF]

Transl Cancer Res
Xia J, He T, Hu Y, Zhou D, Zou D, Li Y, Zhang M, Li B, Wang M, Liu X, Huang Z, Su S, Peng J.   +12 more
europepmc   +1 more source